VM26和VP16 - 213的临床药理学。简要概述。 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

VM26和VP16 - 213的临床药理学。简要概述。 - Suppr | 超能文献

The clinical pharmacology of VM26 and VP16-213. A brief overview.

作者信息

Creaven P J

出版信息

Cancer Chemother Pharmacol. 1982;7(2-3):133-40. doi: 10.1007/BF00254535.

DOI:10.1007/BF00254535

Abstract

摘要

相似文献

1

The clinical pharmacology of VM26 and VP16-213. A brief overview.VM26和VP16 - 213的临床药理学。简要概述。

Cancer Chemother Pharmacol. 1982;7(2-3):133-40. doi: 10.1007/BF00254535.

2

Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.替尼泊苷（VM26）和依托泊苷（VP16 - 213）在癌症患儿中的药代动力学。

Cancer Chemother Pharmacol. 1982;7(2-3):147-50. doi: 10.1007/BF00254537.

3

Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?表鬼臼毒素衍生物、替尼泊苷和依托泊苷的联合化疗。有药效学依据吗？

Cancer Chemother Pharmacol. 1982;7(2-3):151-6. doi: 10.1007/BF00254538.

4

Current development of podophyllotoxins.鬼臼毒素的当前发展情况。

Cancer Chemother Pharmacol. 1982;7(2-3):93-8. doi: 10.1007/BF00254528.

5

Human cytochrome P450 metabolism of teniposide and etoposide.

J Pharmacol Exp Ther. 1992 May;261(2):491-6.

6

Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.依托泊苷和替尼泊苷。生物分析、代谢及临床药代动力学

Pharm Weekbl Sci. 1988 Jun 17;10(3):101-16. doi: 10.1007/BF01959294.

7

The clinical pharmacology of etoposide and teniposide.依托泊苷和替尼泊苷的临床药理学

Clin Pharmacokinet. 1987 Apr;12(4):223-52. doi: 10.2165/00003088-198712040-00001.

8

The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26.

Drug Metab Rev. 1978;8(1):119-35. doi: 10.3109/03602537808993780.

9

Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.依托泊苷（VP16 - 213）和替尼泊苷（VM26）在人肿瘤中的体外活性比较

Cancer Chemother Pharmacol. 1982;7(2-3):113-5. doi: 10.1007/BF00254531.

10

DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.人肺癌细胞及对依托泊苷和替尼泊苷天然敏感或耐药的细胞核中的DNA断裂。

Cancer Res. 1986 Aug;46(8):3809-16.

引用本文的文献

1

Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.复发/难治性原发性中枢神经系统弥漫性大 B 细胞淋巴瘤的治疗结果：自体干细胞移植的单中心经验。

Int J Hematol. 2013 Sep;98(3):346-54. doi: 10.1007/s12185-013-1403-z. Epub 2013 Jul 19.

2

Recurrent brainstem gliomas treated with oral VP-16.口服依托泊苷治疗复发性脑干胶质瘤。

J Neurooncol. 1993 Feb;15(2):133-9. doi: 10.1007/BF01053934.

3

Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions.

本文引用的文献

1

Analysis of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) by high-pressure liquid chromatography.

J Pharm Sci. 1980 Dec;69(12):1440-1. doi: 10.1002/jps.2600691225.

2

Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.采用高效液相色谱法分析抗癌药物VP 16 - 213和VM 26及其代谢产物。

J Chromatogr. 1980 May 9;182(2):211-20. doi: 10.1016/s0378-4347(00)81625-4.

3

Phase II study of VM-26 in adult malignancies.

Cancer Treat Rep. 1980 Jan;64(1):147-9.

4

依托泊苷的药代动力学：药代动力学参数与临床情况的相关性

Cancer Chemother Pharmacol. 1993;31(5):350-6. doi: 10.1007/BF00686147.

4

Cross-resistance to cytotoxic drugs in human glioma cell lines in culture.培养的人胶质瘤细胞系对细胞毒性药物的交叉耐药性。

Br J Cancer. 1984 Dec;50(6):831-5. doi: 10.1038/bjc.1984.263.

5

Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.VP-16（依托泊苷）在人脑内和脑外肿瘤中的渗透情况。

J Neurooncol. 1984;2(2):133-9. doi: 10.1007/BF00177899.

6

Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.

Cancer Chemother Pharmacol. 1985;15(2):149-52. doi: 10.1007/BF00257526.

7

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.两种表鬼臼毒素衍生物依托泊苷（VP - 16）和替尼泊苷（VM - 26）对源自肺癌小细胞癌患者的细胞系的作用。

Cancer Chemother Pharmacol. 1987;19(1):16-20. doi: 10.1007/BF00296248.

8

Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.依托泊苷（VP16 - 213）的药物监测。接受依托泊苷治疗患者的药代动力学参数与临床及生化数据的相关性。

Cancer Chemother Pharmacol. 1987;20(1):59-66. doi: 10.1007/BF00252961.

9

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.VP - 16 - 213的体外药效学评价及其对化疗的意义。

Cancer Chemother Pharmacol. 1987;19(3):246-9. doi: 10.1007/BF00252980.

10

Pharmacokinetics of anticancer drugs in children.儿童抗癌药物的药代动力学

Clin Pharmacokinet. 1987 Mar;12(3):168-213. doi: 10.2165/00003088-198712030-00002.

High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma.高效液相色谱法测定人血浆中4'-去甲基表鬼臼毒素-9-(4,6-O-亚乙基-β-D-吡喃葡萄糖苷)(VP 16-213)

J Chromatogr. 1981 Jan 2;222(1):141-5. doi: 10.1016/s0378-4347(00)81044-0.

5

Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).

Cancer Chemother Rep. 1971 Dec;55(5):575-81.

6

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).新型抗肿瘤药物4'-去甲基表鬼臼毒素9-(4,6-O-亚乙基-α-D-吡喃葡萄糖苷)(NSC-141540；VP-16-213)的I期临床试验

Cancer Chemother Rep. 1972 Dec;56(6):769-77.

7

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

Cancer Chemother Rep. 1974 Nov-Dec;58(6):901-7.

8

4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26)--a brief review.4'-去甲基表鬼臼毒素-β-D-噻吩亚甲基葡萄糖苷（VM-26）——简要综述

Eur J Cancer (1965). 1973 Jul;9(7):477-82. doi: 10.1016/0014-2964(73)90130-8.

9

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

Eur J Cancer (1965). 1975 Oct;11(10):697-707. doi: 10.1016/0014-2964(75)90043-2.

10

PTG, a new antineoplastic epipodyphyllotoxin.

Clin Pharmacol Ther. 1975 Aug;18(2):227-33. doi: 10.1002/cpt1975182227.